Pregled bibliografske jedinice broj: 839003
Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy
Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy // International journal of gynecological cancer, 25 (2015), 2; 315-319 doi:10.1097/IGC.0000000000000336 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 839003 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy
Autori
Petrić Miše, Branka ; Boraska Jelavić, Tihana ; Strikić, Ante ; Hrepić, Dario ; Tomić, Krešimir ; Hamm, W. ; Tomić, Snježana ; Prskalo, Tomislav ; Vrdoljak, Eduard
Izvornik
International journal of gynecological cancer (1048-891X) 25
(2015), 2;
315-319
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
advanced cervical cancer ; concomitant chemobrachyradiotherapy ; ifosfamide ; cisplatin
Sažetak
OBJECTIVES: Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries. We present long-term outcomes of treatment with a concomitant chemobrachyradiotherapy followed by consolidation chemotherapy regimen. MATERIALS AND METHODS: We treated 118 patients with LACC (International Federation of Gynecology and Obstetrics stages IB2-IVA) with external radiotherapy (50 Gy in 25 fractions) and concomitant chemobrachyradiotherapy (low-dose rate). Chemotherapy was applied during brachyradiotherapy (cisplatin on day 1 in combination with 24-hour infusion of ifosfamide and mesna uroprotection). Four cycles of consolidation chemotherapy were given starting 4 weeks after the second concomitant chemobrachyradiotherapy cycle. RESULTS: After median follow-up period of 99.3 months, we observed acceptable acute and late toxicity, local control rate of 97.5%, and an overall survival of 74.6% at 96 months. CONCLUSIONS: Chemobrachyradiotherapy regimen followed by consolidation chemotherapy described in this article is a valuable treatment option for LACC.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split
Profili:
Snježana Tomić
(autor)
Ante Strikić
(autor)
Eduard Vrdoljak
(autor)
Branka Petrić Miše
(autor)
Tihana Boraska Jelavić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE